Hyperthermic intraperitoneal chemoperfusion in combined treatment of locally advanced and disseminated gastric cancer: Results of a single-centre retrospective study

Yarema, Roman; Оhorchak, Мyron; Zubarev, Gennadyi P.; Mylyan, Yuriy; Oliynyk, Yuriy; Zubarev, M.; Gyrya, P.; Kovalchuk, Yuriy; Safiyan, Victor; Fetsych, Тaras

doi:10.3109/02656736.2014.893451

Cited by 43 publications

(49 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They attribute this impressive reduction in peritoneal metastases to HIPEC's ability to damage cancer cells or micrometastases through the synergistic combination of heat and chemotherapy. 24 Yarema et al, 25 similarly report that adjuvant HIPEC in gastric cancer patients with a high risk for peritoneal carcinomatosis (PC) had a PC rate of 11.1% compared with 73.7% in a control group. 25 This reduction in PC led to a significantly improved patient survival rate.…”

mentioning

confidence: 99%

“…24 Yarema et al, 25 similarly report that adjuvant HIPEC in gastric cancer patients with a high risk for peritoneal carcinomatosis (PC) had a PC rate of 11.1% compared with 73.7% in a control group. 25 This reduction in PC led to a significantly improved patient survival rate. 25 HIPEC, thus, holds promise as a prophylactic treatment for gastric cancer patients with a high risk of developing PC.…”

mentioning

confidence: 99%

“…The HIPEC population had decreased gastric cancer-related symptoms than those receiving chemotherapy alone, particularly the presence of malignant ascites was reduced. 16 Similarly, in studies by Facchiano et al, 65 and Yarema et al, 25 they showed that, as well as providing survival benefit associated with CRS-HIPEC, HIPEC alone caused complete clinical regression of the symptoms of malignant ascites in patients with primary gastric cancer with PC. Remarkably, evidence for palliation of malignant ascites via HIPEC had already been described by the late 1990s.…”

mentioning

confidence: 99%

“…25 This reduction in PC led to a significantly improved patient survival rate. 25 HIPEC, thus, holds promise as a prophylactic treatment for gastric cancer patients with a high risk of developing PC.…”

mentioning

confidence: 99%

“…[24][25][26] Macri et al 46 reported a very low rate of peritoneal occurrences (8.3%) with prophylactic HIPEC compared with no treatment (50%) in high-risk patients. They attribute this impressive reduction in peritoneal metastases to HIPEC's ability to damage cancer cells or micrometastases through the synergistic combination of heat and chemotherapy.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Current perspectives on hyperthermic intraperitoneal chemotherapy in gastric cancer

Smith¹,

Kirkpatrick²,

Thomas³

et al. 2017

GICTT

View full text Add to dashboard Cite

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is an effective treatment in a variety of cancers with peritoneal carcinomatosis (PC), especially in pseudomyxoma peritonei for which it is the standard of care. The data for gastric cancer are not as conclusive. This review discusses the effect of HIPEC on gastric cancer survival, the importance of patient selection, the effect of HIPEC on gastric cancer morbidity, translational research on HIPEC, and other recent research on HIPEC in the setting of gastric cancer and/or peritoneal metastases. CRS-HIPEC has been shown to be superior to either CRS alone or systemic chemotherapy alone in terms of improving survival. CRS-HIPEC seems to be the best current treatment for patients with gastric cancer and peritoneal metastases. The international community has recommended it as the treatment for this disease. Prudent patient selection before CRS-HIPEC is recommended as subgroups of patients have been shown to benefit from the treatment, while others have not. Studies on CRS-HIPEC have shown the procedure to have acceptably low rates of morbidity and peri-and postoperative complications as well as significant reductions in the incidence of ascites associated with PC. Translational research on HIPEC supports its use as prophylaxis for prevention of peritoneal metastasis and demonstrates HIPEC to be both effective and safe. Measurement of the tumor marker carcinoembryonic antigen has been shown to be an effective indicator of future outcomes in gastric cancer treated with CRS-HIPEC. Although the treatment outcomes have improved, even current treatment using CRS-HIPEC for gastric cancer with PC the survival rates can be dismal. Thus, the treatment of advanced gastric cancer with PC is an ongoing field of study and future directions of the treatment of gastric cancer with PC may include the use of intraperitoneal immunotherapy.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Current perspectives on hyperthermic intraperitoneal chemotherapy in gastric cancer

Smith¹,

Kirkpatrick²,

Thomas³

et al. 2017

GICTT

View full text Add to dashboard Cite

show abstract

DLL4 overexpression increases gastric cancer stem/progenitor cell self‐renewal ability and correlates with poor clinical outcome via Notch‐1 signaling pathway activation

Zhang

et al. 2016

Cancer Medicine

View full text Add to dashboard Cite

Gastric cancer is one of the most common malignant diseases, and poses a serious threat to the quality of human life. Gastric cancer stem/progenitor cells (GCSPCs) have critical effects on tumor formation, affecting specific features of self‐renewal and differentiation and playing a critical role in metastasis. The Notch‐1 pathway is crucially important to GCSPCs and is regulated by DLL4. In this study, DLL4 and Nestin levels were measured in 383 gastric cancer tissue samples by immunohistochemistry, and the clinico‐pathological features of patients assessed. After DLL4 silencing in selected gastric cancer cell lines, the expression of GCSPC markers and colony formation ability were analyzed and the self‐renewal and differentiation capacities of the cells were evaluated. The relationship between DLL4 levels and Notch‐1 signaling pathway effector amounts was assessed via Western blotting and immunofluorescence. Finally, the tumor formation ability of the gastric cancer cells was evaluated with different levels of DLL4 and multiple cell densities in vivo. Our results indicate that DLL4 expression is associated with TNM stage and cancer metastasis, with high amounts of DLL4 leading to poor outcome. DLL4 silencing inhibited the self‐renewal ability of GCSPCs and increased their multidifferentiation capacity, resulting in reduced GCSPC ratios. DLL4 knockdown also blocked the Notch‐1 pathway, weakening invasion ability and resistance to 5‐FU chemotherapy. In vivo, DLL4 silencing inhibited the tumor formation ability of GCSPCs. In conclusion, DLL4 affects GCSPC stemness, altering their pathological behavior. DLL4 silencing inhibits GCSPC metastatic potential both in vitro and in vivo by impeding Notch‐1 signaling pathway activation, indicating that DLL4 may be a new potential therapeutic target.

show abstract

Review of 2022 PSOGI/RENAPE Consensus on HIPEC

Kusamura,

Bhatt,

van Der Speeten

et al. 2024

Journal of Surgical Oncology

View full text Add to dashboard Cite

The 2022 PSOGI (Peritoneal Surface Oncology Group International) and RENAPE (French Network for Rare Peritoneal Malignancies) consensus on hyperthermic intraperitoneal chemotherapy (HIPEC) was a comprehensive effort aimed at standardizing treatment protocols for various peritoneal malignancies. This initiative is critical due to the wide range of technical variations in HIPEC procedures and the resulting need for standardization to ensure consistent and effective patient care and meaningful audit of multicenter data.

show abstract

Hyperthermic intraperitoneal chemoperfusion in combined treatment of locally advanced and disseminated gastric cancer: Results of a single-centre retrospective study

Abstract: HIPEC is a well-tolerated and effective method of adjuvant therapy for gastric cancer with high risk of intraperitoneal progression. Cytoreduction followed by HIPEC improves survival in patients with limited peritoneal carcinomatosis of gastric origin.

Cited by 43 publications

References 20 publications

Current perspectives on hyperthermic intraperitoneal chemotherapy in gastric cancer

Current perspectives on hyperthermic intraperitoneal chemotherapy in gastric cancer

DLL4 overexpression increases gastric cancer stem/progenitor cell self‐renewal ability and correlates with poor clinical outcome via Notch‐1 signaling pathway activation

Review of 2022 PSOGI/RENAPE Consensus on HIPEC

Contact Info

Product

Resources

About